BMEA
Biomea Fusion, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Biomea Fusion, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
No other changes.
No other changes.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Annual filing, covered
10-K parsed · Mar 24 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 24 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
—
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Biomea Fusion, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Biomea Fusion, Inc..
Biomea Fusion, Inc.
0.57
−0.04 · −6.67%
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $13.0M | 33.67% | +0.02% |
| Vanguardindex-like | $4.2M | 10.81% | +8.96% |
| Marshall Wace | $3.0M | 7.83% | +71.02% |
| Aisling | $3.0M | 7.83% | 0.00% |
| Renaissance Technologies | $2.1M | 5.56% | +10.87% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $13.0M | 33.67% | +0.02% |
| Vanguardindex-like | $4.2M | 10.81% | +8.96% |
| Marshall Wace | $3.0M | 7.83% | +71.02% |
| Aisling | $3.0M | 7.83% | 0.00% |
| Renaissance Technologies | $2.1M | 5.56% | +10.87% |
Expected move
No implied move.